Share on LinkedInShare on LinkedIn

ARTICLE · 29 MAY 2024

Regeneron Files Second BPCIA Complaint Against Celltrion's Proposed EYLEA® Biosimilar CT-P42

On May 17, 2024, Regeneron filed a second infringement litigation against Celltrion's proposed EYLEA® (aflibercept) biosimilar CT-P42, Case No. 1:24-cv-00053 (N.D.W. Va.).

United StatesIntellectual Property

On May 17, 2024, Regeneron filed a second infringement litigation against Celltrion's proposed EYLEA® (aflibercept) biosimilar CT-P42, Case No. 1:24-cv-00053 (N.D.W. Va.). The aBLA for CT-P42 was submitted to the FDA in June 2023. Regeneron's Complaint listed 25 patents, including 8 patents with method of treatment claims, 5 patents with formulation/composition claims, 4 patents with composition of matter claims, 12 patents with manufacturing claims, one patent with device claims, and one patent with packaging claims.

Regeneron previously filed a lawsuit against Celltrion related to CT-P42 in November 2023, Case No. 1:23-cv-00089 (N.D.W. Va.), alleging infringement of 38 of Regeneron's patents (previously reported in BPCIA Litigation Related to Proposed Eylea Biosimilar CT-P42 Filed).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from